{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-016589","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.685453+00:00","generated_at":"2026-05-18T17:48:44.633144+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lipocine doses first patient in Phase 3 trial for oral brexanolone (LPCN 1154) in postpartum depression","bullets":["First patient dosed in pivotal Phase 3 trial of LPCN 1154 (oral brexanolone) for postpartum depression; top line data expected Q2 2026.","Trial is outpatient with no medical monitoring required; 48-hour treatment regimen, randomized, blinded vs placebo in women ≥15 with severe PPD.","Primary endpoint is change from baseline in HAM-D scale; NDA submission targeted for mid-2026 based on Phase 3 data.","Virtual investor event on LPCN 1154 scheduled for July 9, 2025 at 11:00 AM ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-016589","json":"https://secwatch.observer/filing/0001641172-25-016589.json","markdown":"https://secwatch.observer/filing/0001641172-25-016589.md","text":"https://secwatch.observer/filing/0001641172-25-016589.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225016589/0001641172-25-016589-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000164117225016589/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:48:44.633144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}